The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health market with acquisition of Veri.

The current state of weight-loss treatments is about to shift with the forthcoming availability of GLP-1 drugs in the ...

Around 25 percent of U.S. adults said they would consider using prescription weight loss medications, like Ozempic or Wegovy, ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

But that's about to change, as weight-loss treatments will soon be available in pill form. RELATED: What Really Happens If ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, ...